Does the media refer more to NVCR or MMED?

In the previous week, NovoCure and NovoCure both had 4 articles in the media. MiniMed Group's average media sentiment score of 0.26 beat NovoCure's score of -0.27 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral MiniMed Group 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, TFX or NVCR?

NovoCure has lower revenue, but higher earnings than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $1.99B 2.65 -$905.64M -$23.29 N/A NovoCure $655.35M 2.97 -$136.23M -$1.30 N/A

Is TFX or NVCR more profitable?

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to TFX or NVCR?

In the previous week, NovoCure had 1 more articles in the media than Teleflex. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for Teleflex. Teleflex's average media sentiment score of 1.15 beat NovoCure's score of -0.27 indicating that Teleflex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, HAE or NVCR?

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.70 $97.31M $2.04 53.17 NovoCure $655.35M 2.97 -$136.23M -$1.30 N/A

Is HAE or NVCR more profitable?

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% NovoCure -21.25% -44.00% -15.85%

Does the media prefer HAE or NVCR?

In the previous week, Haemonetics had 3 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for Haemonetics and 4 mentions for NovoCure. Haemonetics' average media sentiment score of 0.43 beat NovoCure's score of -0.27 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings and valuation, LIVN or NVCR?

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.10 -$242.47M $3.38 23.08 NovoCure $655.35M 2.97 -$136.23M -$1.30 N/A

Is LIVN or NVCR more profitable?

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% NovoCure -21.25% -44.00% -15.85%

Does the media prefer LIVN or NVCR?

In the previous week, LivaNova had 3 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for LivaNova and 4 mentions for NovoCure. LivaNova's average media sentiment score of 0.53 beat NovoCure's score of -0.27 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ITGR or NVCR?

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.32 $102.81M $3.66 34.52 NovoCure $655.35M 2.97 -$136.23M -$1.30 N/A

Is ITGR or NVCR more profitable?

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to ITGR or NVCR?

In the previous week, Integer had 7 more articles in the media than NovoCure. MarketBeat recorded 11 mentions for Integer and 4 mentions for NovoCure. Integer's average media sentiment score of 0.58 beat NovoCure's score of -0.27 indicating that Integer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

NovoCure (NVCR) Competitors

$16.69 -0.03 (-0.18%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.70 +0.01 (+0.08%)

As of 09/18/2026 07:30 PM Eastern

Compare

NVCR vs. MMED, TFX, HAE, LIVN, and ITGR

Should you buy NovoCure stock or one of its competitors? NovoCure's main competitors and comparable companies include MiniMed Group (MMED), Teleflex (TFX), Haemonetics (HAE), LivaNova (LIVN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NovoCure compare to MiniMed Group?

NovoCure (NASDAQ:NVCR) and MiniMed Group (NASDAQ:MMED) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

NovoCure has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A
MiniMed Group	$3.10B	1.97	-$333M	-$0.68	N/A

In the previous week, NovoCure and NovoCure both had 4 articles in the media. MiniMed Group's average media sentiment score of 0.26 beat NovoCure's score of -0.27 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
MiniMed Group	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure currently has a consensus price target of $21.20, suggesting a potential upside of 27.02%. MiniMed Group has a consensus price target of $23.77, suggesting a potential upside of 9.16%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

MiniMed Group has a net margin of 0.00% compared to NovoCure's net margin of -21.25%. MiniMed Group's return on equity of 0.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
MiniMed Group	N/A	N/A	N/A

84.6% of NovoCure shares are owned by institutional investors. 6.6% of NovoCure shares are owned by company insiders. Comparatively, 0.0% of MiniMed Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

MiniMed Group beats NovoCure on 8 of the 14 factors compared between the two stocks.

How does NovoCure compare to Teleflex?

Teleflex (NYSE:TFX) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Teleflex has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, NovoCure has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

95.6% of Teleflex shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 0.7% of Teleflex shares are held by company insiders. Comparatively, 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
NovoCure	-21.25%	-44.00%	-15.85%

NovoCure has lower revenue, but higher earnings than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.65	-$905.64M	-$23.29	N/A
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A

Teleflex presently has a consensus price target of $152.90, indicating a potential upside of 22.82%. NovoCure has a consensus price target of $21.20, indicating a potential upside of 27.02%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, NovoCure had 1 more articles in the media than Teleflex. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for Teleflex. Teleflex's average media sentiment score of 1.15 beat NovoCure's score of -0.27 indicating that Teleflex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Teleflex beats NovoCure on 9 of the 17 factors compared between the two stocks.

How does NovoCure compare to Haemonetics?

Haemonetics (NYSE:HAE) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Haemonetics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, NovoCure has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
NovoCure	-21.25%	-44.00%	-15.85%

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 6.6% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Haemonetics had 3 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for Haemonetics and 4 mentions for NovoCure. Haemonetics' average media sentiment score of 0.43 beat NovoCure's score of -0.27 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.70	$97.31M	$2.04	53.17
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A

Haemonetics currently has a consensus price target of $99.78, suggesting a potential downside of 8.00%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 27.02%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Haemonetics beats NovoCure on 14 of the 17 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

LivaNova (NASDAQ:LIVN) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
NovoCure	-21.25%	-44.00%	-15.85%

LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, NovoCure has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

LivaNova presently has a consensus price target of $84.13, suggesting a potential upside of 7.84%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 27.02%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, LivaNova had 3 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for LivaNova and 4 mentions for NovoCure. LivaNova's average media sentiment score of 0.53 beat NovoCure's score of -0.27 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.10	-$242.47M	$3.38	23.08
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A

Summary

LivaNova beats NovoCure on 12 of the 16 factors compared between the two stocks.

How does NovoCure compare to Integer?

Integer (NYSE:ITGR) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
NovoCure	-21.25%	-44.00%	-15.85%

Integer currently has a consensus target price of $109.86, suggesting a potential downside of 13.05%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 27.02%. Given NovoCure's stronger consensus rating and higher possible upside, analysts plainly believe NovoCure is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Integer had 7 more articles in the media than NovoCure. MarketBeat recorded 11 mentions for Integer and 4 mentions for NovoCure. Integer's average media sentiment score of 0.58 beat NovoCure's score of -0.27 indicating that Integer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.32	$102.81M	$3.66	34.52
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A

99.3% of Integer shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Integer has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, NovoCure has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Summary

Integer beats NovoCure on 10 of the 16 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.95B	$5.50B	$7.25B	$13.14B
Dividend Yield	N/A	1.79%	2.57%	12.30%
P/E Ratio	-12.84	25.34	275.79	25.40
Price / Sales	2.97	72.24	695.58	114.44
Price / Cash	N/A	32.72	77.42	51.66
Price / Book	5.49	5.69	10.46	6.33
Net Income	-$136.23M	$151.55M	$3.49B	$358.33M
7 Day Performance	7.61%	0.66%	0.59%	1.12%
1 Month Performance	-8.30%	-3.83%	-2.01%	-2.67%
1 Year Performance	31.52%	6.86%	18.09%	6.01%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	2.3369 of 5 stars	$16.69 -0.2%	$21.20 +27.0%	+28.4%	$1.95B	$655.35M	N/A	1,605	News Coverage
MMED MiniMed Group	1.5296 of 5 stars	$21.97 -2.4%	$23.77 +8.2%	N/A	$6.33B	$3.22B	N/A	2,800	Positive News Gap Down High Trading Volume
TFX Teleflex	4.7737 of 5 stars	$130.36 -0.5%	$152.90 +17.3%	-1.2%	$5.55B	$2.25B	N/A	15,500
HAE Haemonetics	1.9496 of 5 stars	$106.16 +3.4%	$99.78 -6.0%	+111.9%	$4.67B	$1.33B	52.04	3,009	News Coverage
LIVN LivaNova	2.6801 of 5 stars	$80.63 +3.1%	$84.13 +4.3%	+39.5%	$4.31B	$1.39B	23.86	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors

NVCR vs. MMED, TFX, HAE, LIVN, and ITGR

How does NovoCure compare to MiniMed Group?

Summary

How does NovoCure compare to Teleflex?

Summary

How does NovoCure compare to Haemonetics?

Summary

How does NovoCure compare to LivaNova?

Summary

How does NovoCure compare to Integer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR vs. The Competition

NovoCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NovoCure (NVCR) Competitors

NVCR vs. MMED, TFX, HAE, LIVN, and ITGR

How does NovoCure compare to MiniMed Group?

Which has preferable earnings & valuation, NVCR or MMED?

Does the media refer more to NVCR or MMED?

Do analysts recommend NVCR or MMED?

Is NVCR or MMED more profitable?

Do institutionals & insiders hold more shares of NVCR or MMED?

Summary

How does NovoCure compare to Teleflex?

Which has more volatility and risk, TFX or NVCR?

Do institutionals and insiders believe in TFX or NVCR?

Is TFX or NVCR more profitable?

Which has higher earnings and valuation, TFX or NVCR?

Do analysts prefer TFX or NVCR?

Does the media refer more to TFX or NVCR?

Summary

How does NovoCure compare to Haemonetics?

Which has more risk and volatility, HAE or NVCR?

Is HAE or NVCR more profitable?

Do insiders and institutionals have more ownership in HAE or NVCR?

Does the media prefer HAE or NVCR?

Which has better earnings & valuation, HAE or NVCR?

Do analysts recommend HAE or NVCR?

Summary

How does NovoCure compare to LivaNova?

Do insiders and institutionals have more ownership in LIVN or NVCR?

Is LIVN or NVCR more profitable?

Which has more risk and volatility, LIVN or NVCR?

Do analysts recommend LIVN or NVCR?

Does the media prefer LIVN or NVCR?

Which has better earnings and valuation, LIVN or NVCR?

Summary

How does NovoCure compare to Integer?

Is ITGR or NVCR more profitable?

Do analysts rate ITGR or NVCR?

Does the media refer more to ITGR or NVCR?

Which has preferable earnings & valuation, ITGR or NVCR?

Do insiders & institutionals hold more shares of ITGR or NVCR?

Which has more risk and volatility, ITGR or NVCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR vs. The Competition

NovoCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools